NASDAQ
INVA
Last Price
US $21.19
KEY FIGURES
MKT CAP
$1.6B
EPS
TTM
$4.87
PEG
TTM
0.01x
P/E
TTM
4.36x
P/S
TTM
3.51x
YIELD
0.00%
GROWTH
Revenue Y/Y
4.77%
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $21.19
33.98%
Default assumptions
EBITDA Multiple
Fair Value
Market $21.19
117.79%
Default assumptions
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Innoviva, Inc. cash flow to debt ratio of 73.20% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial risk - Healthy cash flow growth.
Innoviva, Inc.'s free cash flow has decreased -1.06% from $188.42M last year to $186.43M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Innoviva, Inc.'s debt to equity ratio is 0.22, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Innoviva, Inc.'s debt has decreased relative to shareholder equity from 0.65 last year to 0.22 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Innoviva, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Innoviva, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Innoviva, Inc.'s profit margin has increased (1.14K%) in the last year from 6.52% to 80.56%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Innoviva, Inc.'s short-term assets of $727.51M exceed its short-term liabilities of $49.70M
Increasing performance - ROA.
Innoviva, Inc.'s return on assets of 20.98% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Innoviva, Inc.'s return on equity of 30.03%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Innoviva, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Innoviva, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Innoviva, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Innoviva, Inc. has a free cash flow yield of 11.92%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Innoviva, Inc.'s yearly earnings has increased 1.06K% since last year from $23.39M to $271.17M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Innoviva, Inc.'s yearly revenue has increased 18.52% since last year from $358.71M to $425.13M, signaling increasing performance
Increasing performance - ROIC.
ROIC 8.36% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Increasing performance - 3-year revenue CAGR.
Innoviva, Inc.'s 3-year revenue CAGR of 8.66% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Innoviva, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Innoviva, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Undervalued - DCF valuation.
Innoviva, Inc. is undervalued relative to its fair value price of 28.39 based on Discounted Cash Flow model
Undervalued - Earnings yield.
Innoviva, Inc. has an earnings yield of 22.96%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Undervalued - EBITDA valuation.
Innoviva, Inc. is undervalued relative to its fair value price of 46.15 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Innoviva, Inc. has an EV/EBITDA ratio of 3.34x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Innoviva, Inc. has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Innoviva, Inc. has a price-to-book ratio of 1.26x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Innoviva, Inc. has a price-to-sales ratio of 3.51x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
30.03%
Return on equity
ROIC: 8.36%
Valuation History
4.2X
Price to Earnings
EV/EBITDA: 1.5X
Cash flow
Profit margin
0.59%
(FY vs FY)
Cash flow Y/Y
-9.85%
(FY vs FY)
Base valuations use default assumptions. Customize in the Valuator.